BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sloning BioTechnology GmbH Further Strengthens its Intellectual Property with New US Patent


4/14/2010 2:42:13 PM

Puchheim, Germany – April 13, 2010 / b3c newswire / – Sloning, leading supplier of synthetic biology tools was awarded US Patent No, 7,695,906. Sloning’s enabling platform technology - Slonomics® - allows researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes.

Key to Sloning’s success is the company’s core technology, Slonomics®, a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries - 'one codon at a time'. For library production, multiple codons can be introduced in parallel at any desired sequence position. The absence of functional bias and the ability to select and precisely control delivery of up to 20 codons at any ratio results in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.

With over 1000 combinatorial libraries fabricated since the introduction of the Slonomics® technology at the end of April 2008, Sloning has established a market leadership position and serves the majority of the world’s top 50 protein engineering and pharmaceutical companies. Sloning´s technology affords their customers the ability to precisely design an antibody and enzyme library to their exact specifications.

“The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer” says Dr. Jan Van den Brulle, Scientific Director of Sloning R&D.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES